FILGRASTIM
Plasmacytosis
University of Colorado, Denverprotein_peptidePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Plasmacytosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE University of Colorado, Denver | Phase 1/2 | CCC |
Bortezomib University of Colorado, Denver | Phase 1/2 | CCC |
Evomela University of Colorado, Denver | Phase 1/2 | CCC |
PREDNISONE TABLETS University of Colorado, Denver | Phase 1/2 | CCC |
Cyclophosphamide University of Colorado, Denver | Phase 1/2 | CCC |
Inno-206 University of Colorado, Denver | Phase 1/2 | CCC |
Carfilzomib M.D. Anderson Cancer Center | Phase 1 | CC |
Panobinostat M.D. Anderson Cancer Center | Phase 1 | CC |
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →